Efficacy and safety of selective serotonin reuptake inhibitors for diabetes mellitus with depression: a systematic review and meta-analysis
In brief
SSRIs cut depression scores by ~1 point after six months in diabetics
In a meta-analysis of nine trials involving 770 patients with diabetes and depression, SSRIs lowered clinician-rated depression scores by roughly one point only when treatment lasted six months or longer. However, they raised anxiety scores modestly and had no impact on blood sugar or body weight, so clinicians should weigh modest mood benefits against potential anxiety and monitor patients closely.
- Journal
- Frontiers in endocrinology (Q1)
- Published
- 22 July 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Yuqing Zhang, Shilin Liu, Andong Li, Zheng Nan
- PMID
- 42558439
- DOI
- 10.3389/fendo.2026.1891729
Why clinicians should know about it
- Picked for Endocrinology, Diabetes and Metabolism (top studies of the week, 9 August 2026).
- Picked for Psychiatry and Mental Health (top studies of the week, 9 August 2026): SSRIs efficacy in diabetes with depression
Abstract
OBJECTIVES: To evaluate the efficacy and safety of selective serotonin reuptake inhibitors (SSRIs) in patients with diabetes mellitus and comorbid depression. METHODS: This study was registered in PROSPERO (CRD420261305439). Eight electronic databases were searched up to February 11, 2026 for randomized controlled trials comparing SSRIs plus usual care versus control. Outcomes included depressive symptoms (HDRS, BDI), anxiety (HARS), glycaemic control (HbA1c, FPG, PPG), and BMI. Meta-analyses were performed using random-effects models; subgroup analysis by follow-up duration and sensitivity analysis were conducted. RESULTS: Nine RCTs (770 participants) were included. Overall, SSRIs did not significantly improve HDRS (MD = 0.16, 95% CI -0.69 to 1.01, P = 0.72) or BDI scores. However, subgroup analysis showed significant HDRS reduction when follow-up was ≥ 6 months (MD = -0.96, 95% CI -1.86 to -0.05, P = 0.04). SSRIs were associated with increased HARS scores (MD = 2.37, 95% CI 0.73 to 4.02, P = 0.005). No significant effects were observed for HbA1c, FPG, PPG, or BMI. CONCLUSION: Preliminary evidence suggests that SSRIs may offer modest antidepressant benefits when used for ≥ 6 months in diabetic patients with depression, but they may be associated with a small increase in anxiety scores and do not appear to improve glycaemic control or BMI. However, the overall certainty of evidence is low to moderate. Monitoring of early anxiety symptoms is recommended, and further high-quality RCTs are needed. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD420261305439.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.